Xuehua Zhou

Xuehua Zhou

Auto-generated profile, based on publicly available information

Xuehua Zhou

Department of Pediatrics, Xijing Hospital, The Fourth Military Medical University, Xi’an, Shaanxi, China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2023 in Therapeutic Advances in Respiratory Disease
Verified
Journal Article
Open access
XZXuehua Zhou
Xuehua Zhou
PZPanpan Zhang
Panpan Zhang
HTHong Tan
Hong Tan
BDBo Dong
Bo Dong
ZJZenghui Jing
Zenghui Jing
XSXin Sun
Xin Sun
At present, medications containing inhaled corticosteroids (ICS-containing) are the keystones of asthma treatment. The majority of asthmatic children can significantly improve clinical outcomes with little worsening by standardized inhaled glucocorticoid treatment, but there is still a small proportion of children who are unable to achieve good symptom control even after the maximum standardized treatment, known as ‘children with difficult-to-treat asthma (DA)’. The high heterogeneity of DA makes therapy challenging and expensive, which poses a serious risk to children’s health and makes it extremely difficult for clinical physicians to accurately identify and treat children with DA. This article reviews the definition, evaluation, and treatment of this asthma in order to provide a reference for optimal clinical decision-making.